Select Medical Stock Soars 13.86% on Earnings Report

On April 8, 2025, Select Medical's stock surged by 13.86% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Select Medical recently reported its Q4 earnings, which fell short of analysts' estimates, leading to a 7.2% drop in its stock price. The company projected revenues to be between $5.4 billion and $5.6 billion, indicating a cautious outlook for the coming quarters.

In another development, UBS Group revised its price target for Select Medical, lowering it from $40.00 to $21.00 and maintaining a "neutral" rating on the stock. This adjustment reflects the market's concerns over the company's financial performance and future prospects.

Despite beating Q2 earnings estimates, Select Medical's stock experienced a 16.9% decline. The company expects its adjusted EBITDA to fall between $845 million and $885 million, highlighting the challenges it faces in maintaining profitability.